Alopecia areata
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Alopecia areata ti farahan lórí apa irun ori. Ní àwọn ọ̀ràn àpẹẹrẹ, ó hàn ní kíákíá pẹ̀lú ojú tó ṣìṣẹ́̀dá patapata àti ìwọn 2‑3 cm.
relevance score : -100.0%
ReferencesAlopecia areata jẹ́ àìlera kan níbi tí eto ajẹsara rẹ̀ ti ń kọlu àwọn follicle irun, tí ó sì ń yọrí sí pípadà irun nígbà díẹ̀ láìsí àìlera míì. Ó lè farahàn gẹ́gẹ́ bí àbùlù pípadà irun tàbí ó lè ní ipa lórí gbogbo orí tàbí ara, tó ń kan 2 % àwọn ènìyàn ní àkókò kan nígbà ìgbésí ayé wọn. Àsàyàn àkọ́kọ́ ń tọ́ka sí dínkù ààbò àdáyébá tó yí àwọn follicle irun ká.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata jẹ ipo kan tí eto ajẹsara kọlu àwọn irun ori, tí ó ń fa pipadanu irun lórí ori àti àwọn ẹya ara irun míì. Ó kan bíi 2 % ti àwọn ènìyàn káàkiri ayé. Bí ó tilẹ̀ jẹ́ pé ó lè ṣẹlẹ̀ ní gbogbo ọjọ́‑ori, ó wọ́pọ̀ jùlọ ní àwọn ọmọde ju àwọn agbalagba lọ (1.92 % vs. 1.47 %). Àwọn obìnrin, pàápàá jùlọ àwọn tó ju ọdún 50 lọ, máa ń ní iriri rẹ̀ pọ̀ sí i ju àwọn ọkùnrin lọ. Abẹrẹ corticosteroids taara sínú àwọn agbègbè tí ó kan ti fihan àwọn abajade tó dára jùlọ ju lílo wọn lórí àgbáyé.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata ni a gbagbọ pé ó jẹ́ arun autoimmune tí ó ní í ṣe pẹ̀lú eto ajẹsara ti àwọn follicle irun. Ilana ipilẹ ni pé ara kò lè mọ ara rẹ̀, èyí tí ń yọrí sí iparun follicle irun.
○ Itọju – Oògùn OTC
Diẹ̀ nínú àwọn ènìyàn tí ó ní alopecia areata tó kéré lè padà sí ipo deede ní àkókò ọdún kan láì ní itọju. Síbẹ̀, ọ̀pọ̀ ènìyàn máa ń ní àìlera tó ń yọ̀ sí àgbègbè àìlòye lórí orí.
#Hydrocortisone cream
○ Itọju
Abẹrẹ corticosteroid intralesional ni itọju tó munadoko jùlọ. Imunotherapy lè wúlò fún àwọn àgbègbè tó gbooro jùlọ lórí orí.
#Triamcinolone intralesional injection
#DPCP immunotherapy